Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1122 | 979 | 1237 | 1211 | 1480 | 2148 |
Fund Return | 12.24% | -2.06% | 23.67% | 6.58% | 8.16% | 7.94% |
Place in category | 111 | 824 | 144 | 120 | 246 | 79 |
% in Category | 4 | 38 | 7 | 6 | 14 | 6 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
GS India Equity Portfolio E Acc | 4.72B | 21.63 | 10.60 | 11.43 | ||
Goldman Sachs Global CORE Equity Pe | 4.7B | 19.37 | 7.55 | 10.13 | ||
GS Global CORE Equity Portfolio E C | 4.7B | 19.50 | 7.40 | 10.13 | ||
GS Global CORE Equity Portfolio I E | 4.7B | 20.79 | 8.80 | 11.59 | ||
GS EM Equity Portfolio E Acc | 3.23B | 13.36 | -6.07 | 4.49 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
European Growth Fund A Acc EUR | 158.15M | 12.55 | 4.13 | 5.59 | ||
European Growth Fund E Acc EUR | 20.79M | 11.84 | 3.35 | 4.80 | ||
European Growth Fund Y Acc EUR | 198.13M | 13.30 | 5.02 | 6.46 | ||
European Growth Fund Y DIST EUR | 64.28M | 13.33 | 5.02 | 6.47 | ||
European Growth Fund A DIST Eue | 6.54B | 12.54 | 4.13 | 5.59 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 4.44 | 750.9 | +4.03% | |
Nestle | CH0038863350 | 3.64 | 76.00 | +0.05% | |
SAP | DE0007164600 | 3.37 | 225.900 | +0.53% | |
Roche Holding Participation | CH0012032048 | 3.34 | 254.30 | +1.27% | |
Novartis | CH0012005267 | 3.25 | 93.68 | +2.32% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Strong Buy |
Technical Indicators | Strong Buy | Sell | Strong Buy |
Summary | Strong Buy | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review